Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Dec 1, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Studies for the Month of November

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

CITN-12: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm. Cancer Immunotherapy Trials Network; Uldrick, Thomas S. (301) 402-6296

 

PBTC-047: Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma. Pediatric Brain Tumor Consortium; Monje, Michelle. (650) 736-0885

 

Phase II

ADVL1522: A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND#: 126953, NSC#: 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma. Children’s Oncology Group; Geller, James Ian. (513) 636-6312 X 6312

 

AOST1321: Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Janeway, Katherine Anne. (617) 632-4994

 

AOST1421: A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma. Children’s Oncology Group; Hingorani, Pooja. (602) 546-0920

 

Other Phases

AALL14B7-Q: Screening Low-Hypodiploid B-ALL for Pro-B Phenotypes. Children’s Oncology Group; Carlson, Christopher. (206) 667-7034

 

AAML15B5-Q: The Role of Id1 in Leukemogenesis. Children’s Oncology Group; Wang, Lan. (305) 243-8920

 

AEWS15B1-Q: Development of Specific and Reversible LSD1 Inhibitors for Ewing’s Sarcoma. Children’s Oncology Group; Lessnick, Stephen L. (415) 476-3831

 

AEWS15B1-Q: Development of Specific and Reversible LSD1 Inhibitors for Ewing’s Sarcoma. Children’s Oncology Group; Lessnick, Stephen L. (415) 476-3831

 

ANHL14B1-Q: Genomic Analysis of Pediatric Anaplastic Large Cell Lymphoma ALCL. Children’s Oncology Group; Leventaki, Vasiliki. (901) 595 7531

 

APEC14B1: The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study. Children’s Oncology Group; Adamson, Peter C. (215) 590-6359

 

E1608T2: Inherited Markers as Predictors of Adverse Events and Survival Among Melanoma Patients Treated with Ipilimumab. ECOG-ACRIN Cancer Research Group; Nathanson, Katherine Leah. (215) 573-9840

 

S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer. SWOG; Shankaran, Veena (206) 288-7456



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter